Allergan to Buy MAP Pharmaceuticals for $958 Million

Allergan, Inc., has agreed to pay nearly $1 billion to acquire MAP Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing new therapies in neurology, the two companies announced in a news release. The purchase price of $25 a share in cash is a 60% premium over MAP’s closing price of $1...

Full Story →